HOME >> BIOLOGY >> NEWS
Hypothermia helps brain heal after cardiac arrest, finds University of Pittsburgh study

BOSTON, May 30 Cooling body temperature to levels consistent with hypothermia improves survival when induced after cardiac arrest and also promotes growth factors important for the brains recovery, suggests a study performed by researchers in the department of emergency medicine at the University of Pittsburgh School of Medicine. Preliminary results of their study were reported today at the 2003 Annual Meeting of the Society of Academic Emergency Medicine (SAEM) in Boston.

Although the study involved animals, the findings already had an influence on the management of cardiac arrest patients being treated at the University of Pittsburgh Medical Center (UPMC), where the lead researcher is also a practicing emergency medicine physician.

Cardiac arrest is the sudden, abrupt loss of heart function. Death usually occurs within minutes unless cardiopulmonary resuscitation (CPR) and rapid defibrillation is available. As cardiac arrest progresses, blood flow to the brain ceases. If a patient survives long enough to make it to the hospital, the patient often will be in a coma and at risk of permanent brain injury. In fact, less than 10 percent of patients make it through the chain-of-survival (early access to care, early CPR, early defibrillation and early advanced care). The Pitt researchers sought to find out if hypothermia treatment played a role in survival from cardiac arrest and brain recovery.

In animal studies, the researchers found that when the animals were cooled to 33 degrees Celsius (91.4 degrees Fahrenheit) beginning one hour after cardiac arrest, there was 100 percent survival, whereas 75 percent of the animals left at normal temperature of 37C (98.6F) survived. Furthermore, microscopic brain injury was reduced by half, and some animals showed functional improvement in as little as 12 hours after cardiac arrest was induced. Conversely, the animals left at normal temperature after cardiac arrest showed little or no functional improveme
'"/>

Contact: Maureen McGaffin
412-647-3555
University of Pittsburgh Medical Center
30-May-2003


Page: 1 2

Related biology news :

1. Atacama rover helps NASA learn to search for life on Mars
2. Reducing allergens in the home helps inner-city children with asthma
3. As informatics grows, Indiana University helps set research agenda
4. New diagnostic technology helps justify earlier cataract surgery
5. New technique helps scientists reveal interactions between genes and drugs
6. Living at home helps young mothers stay in school
7. Hormone helps fish to mate, may affect human hearing
8. Harmless virus helps slow HIV by boosting immune proteins
9. Study helps explain island populations susceptibility to exotic diseases
10. Utah scientist helps discover new mouse species -- and maybe a new genus
11. Choice of food helps hungry caterpillar

Post Your Comments:
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
(Date:8/4/2015)... Research and ... addition of the "Digital Forensics Market ... (Computer Forensics, Network Forensics, Mobile Device Forensics, ... and Region - Global Forecast to 2020" ... By Component (Hardware, Software, and Service), Sub-Segment ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel ... stage regenerative medicine company focused on the development ... for the quarter ended June 30, 2015, corporate ... and management report are available at www.sedar.com ... . "RepliCel expects to launch ...
(Date:8/28/2015)... ... ... the initial launch of FireflySci Inc. (FFS) in early 2015, the company continues to shake ... as the Fonz in a lab coat and Large Marge have been posted on the ... , FireflySci is proud to be the only cuvette manufacturer is the world that ...
(Date:8/27/2015)... Reston, VA (PRWEB) , ... August 27, 2015 , ... ... government contractors solve complex business problems, is pleased to announce their ranking as one ... 34th annual ranking of the fastest-growing private companies across the nation. , “It is ...
(Date:8/27/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... Pharmaceutical Holding Company Limited (Biohaven), announced today that ... of BHV-0223, a glutamate modulating agent. Biohaven filed ... recently obtained clearance from the U.S. Food and ... Portage holds 54% equity interest in Biohaven, a ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
Cached News: